Liquid biopsies have emerged as a promising method to investigate the genomic landscape evolution of the whole tumor compartment since they reflect the tumor-specific genetic profile of the primary tissue. However, so far, their analysis has only been implemented as therapy decision-maker in solid tumors. Hematologic malignancies are characterized by complex and constantly changing genomic aberrations that are relevant in terms of prognosis, and therapy response monitoring. Liquid biopsies can be representative of the whole bone marrow compartment and of extramedullary sites in contrast to the sampling of a single bone marrow site, and might be an alternative to the biopsy procedure. However, standardization and validation of the techniques are necessary before integrating liquid biopsies in the clinical practice.
Liquid biopsy is the process of molecular evaluation of cell-free nucleic acids, metabolites, proteins, subcellular structures including exosomes, and circulating tumor cells in body fluids. Potential advantages of liquid biopsies include their minimally invasive nature, and the possibility of longitudinal monitoring. They are particularly useful for determining minimal residual disease, stratifying recurrence risk, and evaluating tumor dynamics to predict and monitor disease response and/or resistance to therapy. The aim of this Research Topic is to synthesize the available evidence regarding the current status and the future perspectives on the role of liquid biopsies in the management of patients with hematologic disorders.
We welcome Original Research Articles and Review Articles based on, but not limited to the following research areas:
• Current status of liquid biopsies in hematologic disorders
• Methodological considerations for routine implementation of liquid biopsies in hematologic disorders
• Novel analytical methods of liquid biopsies
• The role of liquid biopsies for minimal residual disease detection and longitudinal monitoring
• The role of liquid biopsies for the early detection of disease response and relapse
• Incorporating liquid biopsies in clinical trials
• How to integrate liquid biopsies in the current treatment algorithm of hematologic malignancies
• The potential future role of liquid biopsies in hematologic malignancies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Liquid biopsies have emerged as a promising method to investigate the genomic landscape evolution of the whole tumor compartment since they reflect the tumor-specific genetic profile of the primary tissue. However, so far, their analysis has only been implemented as therapy decision-maker in solid tumors. Hematologic malignancies are characterized by complex and constantly changing genomic aberrations that are relevant in terms of prognosis, and therapy response monitoring. Liquid biopsies can be representative of the whole bone marrow compartment and of extramedullary sites in contrast to the sampling of a single bone marrow site, and might be an alternative to the biopsy procedure. However, standardization and validation of the techniques are necessary before integrating liquid biopsies in the clinical practice.
Liquid biopsy is the process of molecular evaluation of cell-free nucleic acids, metabolites, proteins, subcellular structures including exosomes, and circulating tumor cells in body fluids. Potential advantages of liquid biopsies include their minimally invasive nature, and the possibility of longitudinal monitoring. They are particularly useful for determining minimal residual disease, stratifying recurrence risk, and evaluating tumor dynamics to predict and monitor disease response and/or resistance to therapy. The aim of this Research Topic is to synthesize the available evidence regarding the current status and the future perspectives on the role of liquid biopsies in the management of patients with hematologic disorders.
We welcome Original Research Articles and Review Articles based on, but not limited to the following research areas:
• Current status of liquid biopsies in hematologic disorders
• Methodological considerations for routine implementation of liquid biopsies in hematologic disorders
• Novel analytical methods of liquid biopsies
• The role of liquid biopsies for minimal residual disease detection and longitudinal monitoring
• The role of liquid biopsies for the early detection of disease response and relapse
• Incorporating liquid biopsies in clinical trials
• How to integrate liquid biopsies in the current treatment algorithm of hematologic malignancies
• The potential future role of liquid biopsies in hematologic malignancies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
